Benzinga

JUNE 21, 2023

The round was led by new investor Lightspeed Venture Partners , with participation from Venrock, Avidity Partners, OMERS Growth Equity and Fidelity Management & Research Company.

Finance 40

Finance Technology Equity 40

Benzinga

FEBRUARY 23, 2023

Combined company will be focused on advancing Enliven's clinical-stage pipeline of precision oncology programs Shares to trade on Nasdaq under the new ticker symbol "ELVN" on February 24, 2023 Combined company is expected to have cash runway into early 2026 BOULDER, Colo., 23, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc.

Marketability 40

Marketability Finance 40

Benzinga

OCTOBER 13, 2022

Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programs. Combined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026.

Finance 40

Finance Marketability 40

Benzinga

MAY 3, 2023

The combined company will focus on advancing Dianthus' pipeline of next-generation complement inhibitors, including DNTH103 currently in a Phase 1 clinical trial. Upon completion of the merger, the combined company is expected to operate under the name Dianthus Therapeutics, Inc. ET CAMBRIDGE, Mass.,

Finance 40

Finance Technology Marketability 40